Introduction {#Sec1}
============

It is well documented that patients with rheumatoid arthritis (RA) are at an increased risk of cardiovascular disease (CVD) and experience higher rates of cardiovascular (CV) morbidity and mortality than the general population \[[@CR1]--[@CR4]\]. While traditional CVD risk factors---including cholesterol levels---may contribute to this heightened risk in patients with RA, they do not completely account for the increased incidence of CV events \[[@CR5], [@CR6]\]. In addition to traditional CVD risk factors, the systemic inflammation associated with RA also plays a role in increasing CVD risk in patients \[[@CR7]\]. Decreasing inflammation is thought to decrease CV morbidity and mortality in patients with RA \[[@CR8]\]. Tumor necrosis factor inhibitor (TNFi) therapy, in particular, has been shown to improve both RA symptoms and CVD risk and reduce CV morbidity and mortality \[[@CR9], [@CR10]\]. In this study, we measured the levels of selected metabolic analytes in patients with RA who received treatment with etanercept to further understand the effect of TNFi therapy on traditional CVD risk factors.

Materials and methods {#Sec2}
=====================

Study design {#Sec3}
------------

The evaluation of CVD risk factors was an exploratory endpoint in a phase 4, prospective, randomized, double-blind, placebo-controlled study (NCT01313208) to evaluate the efficacy and safety of etanercept in patients with moderately active RA despite disease-modifying anti-rheumatic drug (DMARD) therapy. Patients were randomized 1:1 to receive 50 mg etanercept or placebo every week (QW) for 12 weeks, stratified by current methotrexate (MTX) use (yes/no). At week 12, all patients received 50 mg etanercept QW for another 12 weeks.

Patients {#Sec4}
--------

Eligibility criteria have been previously published \[[@CR11]\]. In particular, patients were required to have moderately active RA, as defined by their disease activity score based on 28 joints (DAS28) with C-reactive protein (CRP) as the indicator of inflammation (3.2 \< DAS28-CRP ≤ 5.1).

Subpopulations of interest {#Sec5}
--------------------------

Patients were further categorized based on diabetes and hyperlipidemia. Patients with diabetes were defined as those with a current history of diabetes (stop date in medical history missing or after enrollment date), and/or taking insulin, and/or taking oral anti-diabetics. Patients with hyperlipidemia were defined as those with a current history of hyperlipidemia or hypercholesterolemia (stop date in medical history missing or after enrollment date) and/or taking statins.

Objective {#Sec6}
---------

The objective of this study was to evaluate changes in metabolic CVD risk factors in patients with moderately active RA treated with etanercept.

Outcomes {#Sec7}
--------

The metabolic analytes measured in this study were fasting glucose, fasting insulin, hemoglobin A1C, total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, apolipoprotein A1, apolipoprotein B, adiponectin, leptin, and plasma N-terminal pro b-type natriuretic peptide (NT-proBNP). Shifts in grade (low, normal, high) for each analyte from baseline to week 24 were also measured.

Statistical analyses {#Sec8}
--------------------

Baseline demographics, disease characteristics, and metabolic parameters were summarized descriptively for the overall study population and diabetic and hyperlipidemic subpopulations by treatment groups and time points. Changes in metabolic parameters over time during the study are also displayed graphically.

Human rights {#Sec9}
------------

The study protocol and informed consent form were approved by the applicable Independent Ethics Committee (IEC) or Institutional Review Board (IRB). Patients were informed of all aspects of the study, and the forms were obtained before patients entered the study.

Results {#Sec10}
=======

Demographic and clinical characteristics at baseline {#Sec11}
----------------------------------------------------

A total of 210 patients were enrolled in this study. During the first 12 weeks, 104 patients were randomized to placebo and 106 patients were randomized to etanercept (Table [1](#Tab1){ref-type="table"}). The double-blind phase was completed by 95 % of patients: 94 % placebo and 95 % etanercept (Fig. [1](#Fig1){ref-type="fig"}). The open-label phase was completed by 91 % of patients: 89 % placebo-etanercept and 93 % etanercept-etanercept. Overall, the patients had a mean (standard deviation \[SD\]) age of 56 (12) years, were 77 % female, were 87 % white, had a mean (SD) RA duration of 8 (10) years, and had a mean (SD) disease severity (as measured by DAS28-CRP) of 4.9 (0.8) (Table [1](#Tab1){ref-type="table"}). There were 14 % of patients with a medical history of diabetes and 30 % with a medical history of hyperlipidemia or hypercholesterolemia. There were 22 % of patients receiving statins, 11 % anti-diabetic oral agents, 3 % insulin, and 52 % prednisone.Table 1Demographic and clinical characteristics at baselineCharacteristicPlacebo-etanerceptEtanercept-etanerceptTotal*n* = 104*n* = 106*n* = 210Sex (female), *n* (%)86 (82.7)75 (70.8)161 (76.7)Race (white), *n* (%)90 (86.5)93 (87.7)183 (87.1)Age (years), mean (SD)55.5 (12.8)56.5 (12.1)56.0 (12.4)DAS28-CRP, mean (SD)4.9 (0.8)4.9 (0.7)4.9 (0.8)CRP (mg/L), mean (SD)9.4 (16.3)7.6 (11.8)8.5 (14.2)ESR (mm/h), mean (SD)30.8 (23.5)30.3 (22.8)30.6 (23.1)Tobacco, *n* (%) Never49 (47.1)54 (50.9)103 (49.0) Former35 (33.7)34 (32.1)69 (32.9) Current20 (19.2)18 (17.0)38 (18.1)RA duration (years), mean (SD)7.4 (8.1)8.3 (11.2)7.8 (9.8)RA medication history, *n* (%)103 (99.0)106 (100.0)209 (99.5) DMARDs (nonbiologic)103 (99.0)105 (99.1)208 (99.0) NSAIDs70 (67.3)75 (70.8)145 (69.0) Corticosteroids68 (65.4)73 (68.9)141 (67.1) Analgesics44 (42.3)38 (35.8)82 (39.0) Biologics10 (9.6)10 (9.4)20 (9.5) Other1 (1.0)0 (0.0)1 (0.5)Type 2 diabetes mellitus^a^, *n* (%)12 (11.5)17 (16.0)29 (13.8)Hyperlipidemia^b^, *n* (%)30 (28.8)33 (31.1)63 (30.0)Other medication history, *n* (%) Statin21 (20.2)26 (24.5)47 (22.4) Insulin2 (1.9)4 (3.8)6 (2.9) Oral anti-diabetic10 (9.6)12 (11.3)22 (10.5) Prednisone53 (51.0)57 (53.8)110 (52.4)*SD* standard deviation, *DAS28* disease activity score based on 28 joints, *CRP* C-reactive protein, *ESR* erythrocyte sedimentation rate, *RA* rheumatoid arthritis, *DMARD* disease-modifying anti-rheumatic drug, *NSAID* nonsteroidal anti-inflammatory drug^a^Patients with type 2 diabetes mellitus were defined as those with a current history of diabetes (stop date in medical history missing or after enrollment date), and/or taking insulin, and/or taking oral anti-diabetics^b^Patients with hyperlipidemia were defined as those with a current history of hyperlipidemia or hypercholesterolemia (stop date in medical history missing or after enrollment date) and/or receiving statins Fig. 1Patient disposition. The flow of patients from screening through week 24 of the study. QW every week

Changes in metabolic analytes {#Sec12}
-----------------------------

Levels of CRP decreased in the overall study population by week 24, but there were no significant changes in any other metabolic analytes measured from baseline to weeks 12 and 24 in all patients (Table [2](#Tab2){ref-type="table"}). There were rare elevations in liver function tests and none greater than three times normal.Table 2Summary of analytes in all patients, patients with diabetes, and patients with hyperlipidemiaAnalyte, mean (SD)VisitAllDiabetesHyperlipidemiaPBO-ETNETN-ETNPBO-ETNETN-ETNPBO-ETNETN-ETN*n* = 104*n* = 106*n* = 12*n* = 17*n* = 30*n* = 33Fasting glucose, mg/dLBaseline99.0 (30.7)98.6 (30.3)143.0 (69.2)142.3 (53.1)113.8 (46.2)111.4 (43.5)Week 1295.9 (22.3)97.3 (26.6)127.3 (42.4)133.1 (47.1)104.3 (32.1)105.9 (29.3)Week 24101.0 (22.8)100.1 (24.0)134.8 (35.9)138.4 (35.8)105.3 (26.0)107.6 (17.3)Fasting insulin, mIU/LBaseline14.3 (17.6)16.0 (34.9)24.4 (18.3)40.3 (79.5)22.4 (28.5)26.8 (60.6)Week 1215.3 (22.4)13.2 (13.5)20.2 (15.0)16.1 (21.5)18.0 (16.2)17.7 (17.3)Week 2415.0 (18.4)12.0 (12.1)23.0 (22.7)14.8 (14.0)14.6 (11.9)14.4 (12.8)Hemoglobin A1C, %Baseline5.7 (0.9)5.7 (0.7)7.2 (1.9)6.7 (1.2)6.1 (1.4)6.1 (1.0)Week 125.7 (0.9)5.6 (0.6)7.0 (2.1)6.7 (0.8)5.9 (1.3)6.0 (0.8)Week 245.6 (0.9)5.6 (0.6)6.8 (1.9)6.5 (0.8)5.9 (1.2)5.8 (0.6)Total cholesterol, mg/dLBaseline195.2 (44.2)186.6 (37.1)204.0 (32.9)171.9 (36.6)205.1 (55.1)181.6 (42.5)Week 12190.9 (40.7)184.8 (37.4)205.6 (36.2)170.0 (33.7)190.7 (44.2)182.6 (44.5)Week 24197.0 (41.7)191.1 (39.6)185.5 (32.4)179.9 (37.3)192.8 (44.4)190.5 (43.2)HDL, mg/dLBaseline62.0 (18.1)62.1 (21.7)52.6 (13.2)57.8 (17.1)57.4 (12.3)58.5 (18.0)Week 1260.5 (17.1)61.6 (18.3)54.7 (13.6)61.9 (19.5)56.9 (14.0)61.4 (19.1)Week 2462.1 (18.5)62.2 (22.9)52.1 (14.5)60.6 (15.5)56.0 (13.8)62.1 (18.4)LDL, mg/dLBaseline105.6 (36.3)97.8 (30.0)118.4 (26.9)81.8 (29.5)109.0 (40.7)92.7 (37.2)Week 12103.2 (35.4)96.9 (33.2)112.1 (32.3)79.3 (31.5)102.2 (38.2)90.3 (39.3)Week 24105.5 (35.4)101.7 (31.0)101.9 (89.1)89.1 (31.5)99.0 (34.3)100.0 (33.3)Triglycerides, mg/dLBaseline135.2 (91.6)133.1 (80.1)164.7 (68.6)163.2 (91.6)183.8 (134.1)154.2 (78.0)Week 12139.2 (85.5)131.8 (69.4)221.9 (170.3)153.8 (71.8)167.2 (113.4)155.0 (67.8)Week 24149.6 (104.0)136.6 (76.2)192.8 (165.2)150.7 (71.1)189.8 (141.0)142.0 (74.9)Apolipoprotein A1, mg/dLBaseline159.6 (27.8)160.5 (35.4)152.6 (23.2)158.5 (32.7)158.9 (26.2)159.7 (32.8)Week 12159.2 (28.1)162.0 (32.8)154.8 (25.3)164.1 (30.3)157.5 (27.9)167.8 (34.2)Week 24163.7 (32.1)161.6 (38.0)150.2 (25.7)163.5 (22.5)161.3 (29.8)167.1 (33.4)Apolipoprotein B, mg/dLBaseline91.6 (25.5)86.2 (22.2)106.4 (24.1)79.7 (22.3)101.7 (28.4)86.3 (24.5)Week 1289.5 (24.7)84.9 (23.8)107.3 (25.6)79.6 (20.7)95.5 (26.3)85.8 (25.9)Week 2491.8 (24.2)88.7 (25.0)91.9 (25.3)83.5 (22.9)95.4 (25.2)91.4 (26.9)Adiponectin, mg/LBaseline11.6 (6.8)11.5 (8.7)6.8 (3.4)7.8 (3.8)9.2 (4.7)10.5 (8.2)Week 1211.7 (7.4)11.6 (8.8)7.3 (3.3)8.4 (4.4)9.0 (4.4)10.9 (9.0)Week 2412.3 (7.2)11.6 (9.1)7.7 (3.7)8.1 (4.2)9.7 (4.6)11.5 (9.6)Leptin, μg/LBaseline29.3 (20.9)33.5 (28.5)31.5 (23.0)42.8 (36.6)33.1 (17.0)41.5 (30.2)Week 1230.1 (22.7)35.6 (30.9)30.9 (29.8)44.1 (31.6)34.3 (18.8)43.5 (32.1)Week 2430.8 (22.7)34.5 (28.9)33.7 (25.7)39.3 (25.5)34.1 (22.6)37.8 (22.8)Plasma NT-ProBNP, ng/LBaseline242.0 (554.1)170.1 (334.6)242.1 (513.2)151.0 (153.8)484.0 (935.9)210.8 (535.4)Week 12232.2 (630.8)168.2 (297.8)236.8 (465.8)114.4 (126.5)482.8 (1116.5)158.3 (266.7)Week 24244.2 (687.5)164.2 (315.7)199.8 (382.8)157.5 (229.6)522.4 (1212.0)174.3 (351.1)CRP, mg/LBaseline9.4 (16.3)7.6 (11.8)Week 128.6 (10.8)4.2 (6.2)Week 246.2 (14.0)4.3 (5.5)*SD* standard deviation, *PBO* placebo, *ETN* etanercept, *IU* international unit, *HDL* high-density lipoprotein, *LDL* low-density lipoprotein, *NT-ProBNP* N-terminal pro b-type natriuretic peptide, *CRP* C-reactive protein

The metabolic analytes in patients with diabetes and hyperlipidemia did not change substantially from baseline to week 12 or 24 and were similar to those in the total study population, with some exceptions (Table [2](#Tab2){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}). In patients with diabetes, fasting glucose decreased, HDL increased, and LDL decreased through week 12 in those receiving etanercept. In both subpopulations, fasting insulin decreased through week 12 and hemoglobin A1C decreased slightly through week 24. In addition, apolipoprotein A1 increased (with the exception of patients with diabetes receiving placebo-etanercept) and adiponectin increased slightly through week 24; leptin and apolipoprotein B did not change. Patients at a higher CVD risk experienced no or minimal changes in metabolic analytes from baseline to weeks 12 and 24. All changes that patients did experience were neither statistically nor clinically significant. Metabolic analytes were also compared between patients receiving concurrent nonsteroidal anti-inflammatory drugs and those who were not, among the total study population, patients with diabetes, and patients with hyperlipidemia; responses were similar between groups (data not shown).Fig. 2Changes in metabolic analytes from baseline to weeks 12 and 24. Changes in levels of **a** fasting glucose (mg/dL), **b** fasting insulin (mIU/L), **c** hemoglobin A1C (%), **d** total cholesterol (mg/dL), **e** HDL (mg/dL), **f** LDL (mg/dL), and **g** triglycerides (mg/dL) in all patients (*blue line*); patients with diabetes (*green line*); and patients with hyperlipidemia (*red line*) who received placebo/etanercept (*dotted line*) or etanercept/etanercept (*solid line*) from baseline to weeks 12 and 24. *HDL* high-density lipoprotein, *LDL* low-density lipoprotein

Shifts in grade for analytes {#Sec13}
----------------------------

For the majority of patients, all metabolic analytes were in the normal range at baseline. The majority of patients completed the study week 24 at a normal grade for each analyte measured. Fewer than 25 % of patients in either treatment group experienced a shift in grade between baseline and week 24 for each metabolic analyte measured. Among those who did experience a shift in grade, patients were fairly evenly divided between those who improved in grade and those who worsened.

Discussion {#Sec14}
==========

Treatment with etanercept did not adversely or positively affect the levels of traditional metabolic CVD risk factors in patients with RA. There were no significant changes in these metabolic analytes despite improvements in RA activity parameters, as indicated by decreases in CRP in both groups on etanercept by week 24. Previously reported improvements in CVD risk associated with TNFi therapy may stem from changes in other factors such as decrease in systemic inflammation. Results seen in patients with diabetes and hyperlipidemia demonstrated that there were no changes in traditional metabolic CVD risk factors, even in patients who were at a heightened risk of CVD.

Patients with RA exhibit a lipid paradox, in which patients with untreated RA have lower total cholesterol, HDL, and LDL than the general population, in which these lipid parameters are conventionally at elevated levels when patients are at a higher risk for CVD \[[@CR5], [@CR12], [@CR13]\]. A potential explanation is that higher levels of CRP have been shown to decrease levels of lipids \[[@CR6]\]. Elevated levels of CRP have been shown to independently correlate with increased CVD risk; a previous study has shown that elevated CRP was associated with an up to threefold increase in the risk of a heart attack \[[@CR14]\]. Treatment to control RA subsequently results in an increase in total cholesterol, HDL, and LDL, without a concomitant increase in CVD risk; and in some cases even a decrease in CVD risk \[[@CR6], [@CR12], [@CR13], [@CR15], [@CR16]\]. In our study, patients did not experience any change in levels of lipids, similar to some previous studies \[[@CR15], [@CR17]\].

Treatment with TNFi therapy, including etanercept, has been shown to lower CVD risk in patients with RA \[[@CR18]--[@CR20]\]. Based on analyses in this study and others, the reduction in CVD risk in patients with RA cannot be fully explained by changes in traditional metabolic risk factors. Managing RA symptoms and reducing inflammation in these patients appears to play a key role to decreasing CVD risk \[[@CR8]\]. One study has even shown that the degree to which TNFi therapy reduces disease activity is proportional to the reduction in CVD risk \[[@CR19]\]. One possible explanation behind the beneficial effect of TNFi therapy on CVD risk may relate a reduction in overall inflammation to a reduction in aortic inflammation. Findings from Maki-Petaja and colleagues demonstrated that TNFi therapy reduced aortic inflammation in patients with RA after 8 weeks of treatment, and this effect correlated with a decrease in aortic stiffness \[[@CR21]\]. This study provides further evidence that the main effect of TNFi therapy is on inflammation, which can directly decrease inflammation in the aorta, preventing plaque formation or progression. Similar to reports on TNFi therapy, other biologics (e.g., interleukin-6 receptor inhibitor) also worsen the lipid profile with no worsening of CVD risk \[[@CR22], [@CR23]\].

The well-established benefit of TNFi therapy on CVD risk in patients with RA may also not be apparent in the short term. Recent work by Charles-Schoeman and colleagues demonstrated that patients with early RA in the treatment of early aggressive rheumatoid arthritis (TEAR) trial experienced increases in lipids (total cholesterol, LDL, and HDL) through 24 weeks of treatment with etanercept; these levels began to decrease by 48 weeks of treatment, with statistically significant reductions by week 102 compared with week 24 \[[@CR24]\]. Given this timeline, the time periods evaluated in this manuscript---12 and 24 weeks---may not have been long enough to capture the long-term effects of etanercept treatment on metabolic risk factors. In addition, the study reported here recruited patients with moderate RA with mean a DAS28 of 4.9, compared with the patients with early RA in the TEAR trial who had mean DAS28 ranging from 5.48 to 5.82. The lack of high disease activity in this study may have had an effect on baseline lipid levels, and the small changes in disease activity in response to treatment with etanercept may have had a lesser impact on metabolic parameters. Another possibility why this study did not show any positive effect of etanercept on traditional CVD risk factors may be that this study was underpowered. Larger studies are required to confirm if this conclusion holds true in different populations.

In managing the CVD risk in patients with RA, it is important to evaluate both traditional CVD risk factors and RA severity. As shown in one study, incorporating both sets of factors into a model enhances its ability to predict the incidence rate of CV events \[[@CR25]\]. Furthermore, as described in the European League Against Rheumatism (EULAR) recommendations for CVD risk management in patients with RA, the control of both systemic inflammation and traditional CVD risk factors is important to control CVD risk \[[@CR26], [@CR27]\]. The analysis presented here shows that etanercept controls the systemic inflammation in patients with RA, as evidenced by the reduction of CRP, and does not adversely affect levels of traditional cardiovascular risk factors.
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